Supply Agreements
Biotechnology
Biotechnology (373) | Supply Agreements (2,958)
- 89bio, Inc. (1 contract)
- ACADIA PHARMACEUTICALS INC (1)
- ACHIEVE LIFE SCIENCES, INC. (2)
- Acorda Therapeutics (5)
- Adamas Pharmaceuticals Inc (3)
- Adhera Therapeutics, Inc. (2)
- ADMA BIOLOGICS, INC. (2)
- Advaxis, Inc. (1)
- AGENUS INC (2)
- Aimmune Therapeutics, Inc. (2)
- Akebia Therapeutics, Inc. (11)
- ALBIREO PHARMA, INC. (4)
- Alexion Pharmaceuticals (1)
- Alkermes plc. (5)
- Alliqua BioMedical, Inc. (2)
- Alpha Healthcare Acquisition Corp. (3)
- AMARILLO BIOSCIENCES INC (1)
- AMARIN CORP PLC (9)
- Amgen Inc. (4)
- Anika Therapeutics (1)
- Apellis Pharmaceuticals, Inc. (1)
- Aprea Therapeutics, Inc. (1)
- Aptevo Therapeutics Inc. (1)
- Aravive, Inc. (5)
- Arcturus Therapeutics Holdings Inc. (1)
- Arcutis Biotherapeutics, Inc. (2)
- ARENA PHARMACEUTICALS INC (2)
- Athenex, Inc. (2)
- ATOSSA GENETICS INC (1)
- Aurinia Pharmaceuticals Inc. (2)
- BELLICUM PHARMACEUTICALS, INC (1)
- Biohaven Pharmaceutical Holding Co Ltd. (1)
- BIOTIME INC (2)
- bluebird bio, Inc. (5)
- Bolt Biotherapeutics, Inc. (2)
- Bone Biologics Corp (1)
- Cabaletta Bio, Inc. (1)
- CAPSTAR SPECIAL PURPOSE ACQUISITION CORP. (1)
- CATALYST BIOSCIENCES, INC. (2)
- CATALYST PHARMACEUTICALS, INC. (1)
- Celldex Therapeutics, Inc. (1)
- Cellular Biomedicine Group, Inc. (1)
- Century Therapeutics, Inc. (1)
- ChemoCentryx, Inc. (1)
- CHIMERIX INC (2)
- Conatus Pharmaceuticals Inc. (1)
- CTI BIOPHARMA CORP (1)
- Cyclacel Pharmaceuticals, Inc. (1)
- CytoDyn Inc. (11)
- CYTRX CORP (1)
- Deciphera Pharmaceuticals, Inc. (2)
- Dermavant Sciences Ltd (2)
- DiaMedica Therapeutics Inc. (1)
- DYNAVAX TECHNOLOGIES CORP (10)
- Eagle Pharmaceuticals, Inc. (3)
- Edge Therapeutics, Inc. (1)
- Eiger BioPharmaceuticals, Inc. (1)
- Emergent BioSolutions Inc. (1)
- Equillium, Inc. (1)
- Evelo Biosciences, Inc. (1)
- Exelixis (6)
- FIBROGEN INC (5)
- Flex Pharma, Inc. (1)
- Flexion Therapeutics Inc (8)
- FS Development Corp. (2)
- GALECTIN THERAPEUTICS INC (1)
- Gemphire Therapeutics Inc. (2)
- GENEREX BIOTECHNOLOGY CORP (1)
- Gilead Sciences (8)
- Grail, Inc. (1)
- HEMISPHERX BIOPHARMA INC (3)
- HISTOGENICS CORP (3)
- Homology Medicines, Inc. (1)
- HUMANIGEN, INC (1)
- IMMUCELL CORP (1)
- IMMUNOGEN INC (1)
- INSMED Inc (2)
- Inspyr Therapeutics, Inc. (1)
- INTERCEPT PHARMACEUTICALS, INC. (4)
- IRONWOOD PHARMACEUTICALS INC (3)
- Isoray, Inc. (9)
- Kadmon Holdings, Inc. (2)
- Kindred Biosciences, Inc. (3)
- Kiniksa Pharmaceuticals, Ltd. (1)
- LEXICON PHARMACEUTICALS, INC. (2)
- Ligand Pharmaceuticals Incorporated (11)
- MACROGENICS INC (2)
- MANNKIND CORP (13)
- MATEON THERAPEUTICS INC (1)
- MEI Pharma, Inc. (1)
- Minerva Neurosciences, Inc. (1)
- Myovant Sciences Ltd. (5)
- NantKwest, Inc. (1)
- Natera, Inc. (6)
- NAVIDEA BIOPHARMACEUTICALS, INC. (1)
- NEUROBIOLOGICAL TECHNOLOGIES INC (1)
- Neurotrope, Inc. (1)
- NOVAVAX INC (5)
- OncBioMune Pharmaceuticals, Inc (1)
- ONCOSEC MEDICAL Inc (1)
- OPGEN INC (1)
- Ophthotech Corp. (1)
- PALATIN TECHNOLOGIES INC (3)
- PDL BIOPHARMA, INC. (2)
- PhaseBio Pharmaceuticals Inc (1)
- PORTOLA PHARMACEUTICALS INC (2)
- Progenics Pharmaceuticals, Inc. (1)
- PROGENITY, INC. (2)
- Protalix BioTherapeutics, Inc. (2)
- PUMA BIOTECHNOLOGY, INC. (1)
- Radius Health, Inc. (6)
- Regeneron Pharmaceuticals (7)
- RenovoRx, Inc. (1)
- Retrophin, Inc. (3)
- RIGEL PHARMACEUTICALS INC (1)
- RITTER PHARMACEUTICALS INC (2)
- Sage Therapeutics, Inc. (1)
- Sana Biotechnology, Inc. (2)
- Sarepta Therapeutics, Inc. (1)
- Savara Inc (3)
- SEATTLE GENETICS INC (14)
- Seres Therapeutics, Inc. (1)
- SOLIGENIX, INC. (1)
- SOPHIRIS BIO INC. (1)
- Spectrum Pharmaceuticals, Inc. (9)
- SPHERIX INC (1)
- SYNLOGIC, INC. (1)
- T2 Biosystems, Inc. (6)
- TENAX THERAPEUTICS, INC. (1)
- Translate Bio, Inc. (1)
- TREVENA INC (1)
- Twist Bioscience Corp (2)
- U.S. Stem Cell, Inc. (2)
- Ultragenyx Pharmaceutical Inc. (3)
- United Therapeutics Corp (3)
- UroGen Pharma Ltd. (1)
- Vaxart, Inc. (1)
- Vaxcyte, Inc. (1)
- Vericel Corp (4)
- VICAL INC (5)
- Viela Bio, Inc. (2)
- VITRO DIAGNOSTICS INC (1)
- WINDTREE THERAPEUTICS INC (2)
- Xencor Inc (2)
- Amendment to the Agreement for the Supply of Manufactured Products, dated May 15, 2023, between Intercept Pharma Europe Ltd. and Amdipharm Ltd (INTERCEPT PHARMACEUTICALS, INC., Filed With SEC on May 18, 2023)
- Commercial Manufacturing and Supply Agreement, dated March 14, 2023, between the Registrant and Agilent Technologies, Inc (Ophthotech Corp., Filed With SEC on May 10, 2023)
- Supply Agreement, dated as of February 28, 2018, by and between Spectrum Pharmaceuticals, Inc. and Hanmi Pharmaceuticals Co., Ltd (Spectrum Pharmaceuticals, Inc., Filed With SEC on March 31, 2023)
- First Amendment to Supply Agreement, dated as of December 6, 2019, by and between Spectrum Pharmaceuticals, Inc. and Hanmi Pharmaceuticals Co., Ltd (Spectrum Pharmaceuticals, Inc., Filed With SEC on March 31, 2023)
- Second Amendment to Supply Agreement, dated as of January 1, 2022, by and between Spectrum Pharmaceuticals, Inc. and Hanmi Pharmaceuticals Co., Ltd (Spectrum Pharmaceuticals, Inc., Filed With SEC on March 31, 2023)
- First Amendment to Master Manufacturing Supply Agreement, effective as of November 14, 2022, between the Company and STA Pharmaceutical Hong Kong Limited, a subsidiary of WuXi... (Retrophin, Inc., Filed With SEC on February 23, 2023)
- Fourth Amendment to Commercial Supply Agreement, dated December 22, 2022, by and between MannKind Corporation and United Therapeutics Corporation (MANNKIND CORP, Filed With SEC on February 23, 2023)
- Third Amendment to Commercial Supply Agreement, dated August 31, 2022, by and between MannKind Corporation and United Therapeutics Corporation (MANNKIND CORP, Filed With SEC on February 23, 2023)
- Second Amendment to Commercial Supply Agreement, dated June 15, 2022, by and between MannKind Corporation and United Therapeutics Corporation (MANNKIND CORP, Filed With SEC on February 23, 2023)
- Supply Agreement, dated November 20, 2022, by and between the Registrant and Jack Zamora (VITRO DIAGNOSTICS INC, Filed With SEC on January 30, 2023)
- Form of Supply Agreement between Eisai and the Company (certain identified information has been excluded from the exhibit because it both (i) is not material and (ii) would be... (CATALYST PHARMACEUTICALS, INC., Filed With SEC on December 22, 2022)
- Manufacturing and Supply Agreement, dated May 30, 2020, by and between the Registrant and Isotopia Molecular Imaging Ltd. (the Isotopia Agreement) and the extension to the... (UroGen Pharma Ltd., Filed With SEC on November 10, 2022)
- Amended and Restated SARS-CoV-2 Vaccine Supply Agreement, dated as of July 1, 2022, between the Company and The Secretary of State for Business, Energy, and Industrial Strategy,... (NOVAVAX INC, Filed With SEC on November 9, 2022)
- Letter of Amendment to the Amended and Restated SARS-CoV-2 Vaccine Supply Agreement, dated as of September 26, 2022, between the Company and The Secretary of State for Business,... (NOVAVAX INC, Filed With SEC on November 9, 2022)
- Amendment No. 1 to Sourcing and Supply Agreement, dated July 14, 2022, by and between Amgen USA Inc., a wholly owned subsidiary of Amgen Inc., and DaVita Inc (Amgen Inc., Filed With SEC on November 4, 2022)
- Modification P00001 to Supply Agreement, dated as of March 9, 2021, by and between the Registrant and the U.S. Army Contracting Command, New Jersey (Regeneron Pharmaceuticals, Filed With SEC on November 3, 2022)
- Modification P00002 to Supply Agreement, dated as of June 17, 2021, by and between the Registrant and the U.S. Army Contracting Command, New Jersey (Regeneron Pharmaceuticals, Filed With SEC on November 3, 2022)
- Modification P00003 to Supply Agreement, dated as of July 8, 2021, by and between the Registrant and the U.S. Army Contracting Command, New Jersey (Regeneron Pharmaceuticals, Filed With SEC on November 3, 2022)
- Amendment No. 2 to Supply Agreement, dated effective as of September 30, 2022, by and between the Company and Biological E. Limited (DYNAVAX TECHNOLOGIES CORP, Filed With SEC on November 3, 2022)
- Amendment No. 1 to Supply Agreement, dated effective as of June 23, 2022, by and between the Company and Biological E. Limited (DYNAVAX TECHNOLOGIES CORP, Filed With SEC on November 3, 2022)
- Modification P00007 to Supply Agreement, dated as of July 29, 2022, by and between the Registrant and the U.S. Army Contracting Command, New Jersey (Regeneron Pharmaceuticals, Filed With SEC on November 3, 2022)
- Supply Agreement, dated September 15, 2015, by and between Seres Therapeutics, Inc. and GenIbet BioPharmaceuticals, SA, as amended (Seres Therapeutics, Inc., Filed With SEC on November 2, 2022)
- Second Amendment Agreement, dated March 7, 2022, by and between Sanquin Blood Supply Foundation and Gemini Therapeutics Sub, Inc (FS Development Corp., Filed With SEC on September 2, 2022)
- CERTAIN IDENTIFIED INFORMATION MARKED BY [*] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT... (CytoDyn Inc., Filed With SEC on August 15, 2022)
- CERTAIN IDENTIFIED INFORMATION MARKED BY [*] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT... (CytoDyn Inc., Filed With SEC on August 15, 2022)
- CERTAIN IDENTIFIED INFORMATION MARKED BY [*] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT... (CytoDyn Inc., Filed With SEC on August 15, 2022)
- Exclusive Supply and Distribution Agreement between CytoDyn Inc. and Biomm S.A., dated April 6, 2021 (CytoDyn Inc., Filed With SEC on August 15, 2022)
- Amendment No. 4 to Clinical and Commercial Supply Agreement Viral Vector Product by and between bluebird bio (Switzerland) GmbH and SAFC Carlsbad, Inc (bluebird bio, Inc., Filed With SEC on August 4, 2022)
- Supply Agreement by and between Aurinia Pharmaceuticals Inc. and Otsuka Pharmaceutical Co. Ltd. dated August 1, 2022 (Aurinia Pharmaceuticals Inc., Filed With SEC on August 4, 2022)
- Agreement for the Supply of Manufactured Products, dated May 5, 2022, between IPEL and Amdipharm Limited (Amdipharm) (INTERCEPT PHARMACEUTICALS, INC., Filed With SEC on August 3, 2022)
- Amendment No. 1 to Commercial Supply Agreement dated June 17, 2022 between Seagen Inc. (f/k/a Seattle Genetics, Inc.) and Corden Pharma GmbH (SEATTLE GENETICS INC, Filed With SEC on July 28, 2022)
- Third Amended and Restated Supply and Distribution Agreement, dated June 14, 2022, between Gelesis Holdings, Inc and Roman Health Pharmacy LLC (CAPSTAR SPECIAL PURPOSE ACQUISITION CORP., Filed With SEC on June 21, 2022)
- Amended and Restated Supply Agreement between the Registrant and EirGenix, Inc., dated January 25, 2022 (Bolt Biotherapeutics, Inc., Filed With SEC on May 12, 2022)
- Second Amendment to Co-Development, Supply and Commercialization Agreement, dated as of April 15, 2022, by and between the Registrant and Bharat Biotech International Limited (HISTOGENICS CORP, Filed With SEC on May 6, 2022)
- Modification P00006 to Supply Agreement, dated as of February 24, 2022, by and between the Registrant and the U.S. Army Contracting Command, New Jersey (Regeneron Pharmaceuticals, Filed With SEC on May 4, 2022)
- Manufacturing and Supply Agreement, dated March 10, 2022, by and among Homology Medicines, Inc., Roadrunner Solutions LLC and, solely for purposes of Section 2.3(b)(iii) thereof,... (Homology Medicines, Inc., Filed With SEC on March 23, 2022)
- Licence and Supply Agreement, dated December 30, 2021, by and between the Registrant and Oxford Biomedica (UK) Limited (Cabaletta Bio, Inc., Filed With SEC on March 17, 2022)
- Second Amendment Agreement, dated March 7, 2022, by and between Sanquin Blood Supply Foundation and Gemini Therapeutics Sub, Inc (FS Development Corp., Filed With SEC on March 10, 2022)
- Second Amendment to API Commercial Supply Agreement by and between Amarin Pharmaceuticals Ireland Ltd. and Chemport Inc., dated July 19, 2012 (AMARIN CORP PLC, Filed With SEC on March 1, 2022)
- Amendment No. 4 to Master Manufacturing Services and Supply Agreement, dated as of December 17, 2021, by and between Siegfried Evionnaz SA and Keryx Biopharmaceuticals, Inc (Akebia Therapeutics, Inc., Filed With SEC on March 1, 2022)